Silica-Coated Nanoparticles with a Core of Zinc, l-Arginine, and a Peptide Designed for Oral Delivery
Source abstract
Abstract
Nanoparticle constructs for oral peptide delivery at a minimum must protect and present the peptide at the small intestinal epithelium in order to achieve oral bioavailability. In a reproducible, scalable, surfactant-free process, a core was formed with insulin in ratios with two established excipients and stabilizers, zinc chloride and l-arginine. Cross-linking was achieved with silica, which formed an outer shell. The process was reproducible across several batches, and physicochemical characterization of a single batch was confirmed in two independent laboratories. The silica-coated nanoparticles (SiNPs) entrapped insulin with high entrapment efficiency, preserved its structure, and released it at a pH value present in the small intestine. The SiNP delivered insulin to the circulation and reduced plasma glucose in a rat jejunal instillation model. The delivery mechanism required residual l-arginine in the particle to act as a permeation enhancer for SiNP-released insulin in the jejunum. The synthetic process was varied in terms of ratios of zinc chloride and l-arginine in the core to entrap the glucagon-like peptide 1 analogue, exenatide, and bovine serum albumin. SiNP-delivered exenatide was also bioactive in mice to some extent following oral gavage. The process is the basis for a platform for oral peptide and protein delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Protein purification and stability
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Sanofi Recherche & Développement, PSO/LGCR, Bâtiment BLP, rue du Pr Blayac, 34184 Montpellier Cedex 4, France
Sanofi-Aventis Deutschland GmbH. Industriepark Höchst, K703 65926 Frankfurt, Germany
Sanofi Recherche & Développement, CMC External Innovation, 82, avenue Raspail, 94250 Gentilly Cedex, France
Funding
FP7 Nanosciences, Nanotechnologies, Materials and new Production Technologies · Science Foundation Ireland
References (59)
Show source-provided references
1. 10.3390/molecules2404080910.3390/molecules24040809 ↗
2. 10.1016/j.addr.2016.01.01010.1016/j.addr.2016.01.010 ↗
3. 10.1111/jan.1381810.1111/jan.13818 ↗
4. 10.1530/eje-15-104210.1530/eje-15-1042 ↗
5. 10.1111/dom.1297710.1111/dom.12977 ↗
6. 10.1111/jphp.1285210.1111/jphp.12852 ↗
7. 10.1080/21688370.2016.115680410.1080/21688370.2016.1156804 ↗
8. 10.1016/s2213-8587(18)30372-310.1016/s2213-8587(18)30372-3 ↗
9. 10.1001/jama.2019.294210.1001/jama.2019.2942 ↗
10. 10.1021/acs.chemrev.6b0083810.1021/acs.chemrev.6b00838 ↗
11. 10.1016/j.addr.2016.02.00410.1016/j.addr.2016.02.004 ↗
12. 10.1038/nrd.2018.18310.1038/nrd.2018.183 ↗
13. 10.1126/scitranslmed.aar704710.1126/scitranslmed.aar7047 ↗
14. 10.1210/jc.2014-411310.1210/jc.2014-4113 ↗
15. 10.1080/21688370.2016.117682210.1080/21688370.2016.1176822 ↗
16. 10.1016/j.jconrel.2014.10.02610.1016/j.jconrel.2014.10.026 ↗
17. 10.1016/j.ijpharm.2018.01.01810.1016/j.ijpharm.2018.01.018 ↗
18. 10.1016/j.jconrel.2012.11.00510.1016/j.jconrel.2012.11.005 ↗
19. 10.1016/j.jconrel.2017.02.02410.1016/j.jconrel.2017.02.024 ↗
20. 10.1016/j.jconrel.2018.03.00410.1016/j.jconrel.2018.03.004 ↗
21. 10.1016/j.jconrel.2018.10.02210.1016/j.jconrel.2018.10.022 ↗
22. 10.1016/j.ejpb.2018.09.02310.1016/j.ejpb.2018.09.023 ↗
23. 10.1016/s0140-6736(76)91209-510.1016/s0140-6736(76)91209-5 ↗
24. 10.2337/diab.37.2.24610.2337/diab.37.2.246 ↗
25. 10.1126/scitranslmed.300704910.1126/scitranslmed.3007049 ↗
26. 10.2217/nnm.16.4310.2217/nnm.16.43 ↗
27. 10.1016/j.drudis.2012.06.01410.1016/j.drudis.2012.06.014 ↗
28. 10.1016/j.colsurfb.2017.04.02410.1016/j.colsurfb.2017.04.024 ↗
29. 10.1016/j.ejpb.2015.03.02710.1016/j.ejpb.2015.03.027 ↗
30. 10.1016/j.ijpharm.2014.07.04910.1016/j.ijpharm.2014.07.049 ↗
31. 10.1016/j.ijpharm.2013.06.05110.1016/j.ijpharm.2013.06.051 ↗
32. 10.3389/fchem.2019.0029010.3389/fchem.2019.00290 ↗
33. 10.3390/pharmaceutics11030129.10.3390/pharmaceutics11030129. ↗
34. 10.1080/17425247.2018.150325010.1080/17425247.2018.1503250 ↗
35. 10.1016/j.colsurfb.2018.04.06410.1016/j.colsurfb.2018.04.064 ↗
36. 10.1021/acs.jpcb.8b0655710.1021/acs.jpcb.8b06557 ↗
37. 10.1016/j.ijpharm.2017.01.06610.1016/j.ijpharm.2017.01.066 ↗
38. 10.1016/j.ejpb.2018.10.01310.1016/j.ejpb.2018.10.013 ↗
39. 10.1016/j.jconrel.2019.08.00810.1016/j.jconrel.2019.08.008 ↗
40. 10.1016/j.jconrel.2008.09.09110.1016/j.jconrel.2008.09.091 ↗
41. 10.1016/j.addr.2011.06.01110.1016/j.addr.2011.06.011 ↗
42. 10.1016/j.xphs.2017.11.01510.1016/j.xphs.2017.11.015 ↗
43. 10.1021/acs.jpclett.8b0278510.1021/acs.jpclett.8b02785 ↗
44. 10.1016/j.colsurfb.2018.02.00410.1016/j.colsurfb.2018.02.004 ↗
45. 10.1021/ar300098610.1021/ar3000986 ↗
46. 10.1039/c6nr09331k10.1039/c6nr09331k ↗
47. 10.1016/j.addr.2009.09.00610.1016/j.addr.2009.09.006 ↗
48. 10.1016/j.jconrel.2016.10.00210.1016/j.jconrel.2016.10.002 ↗
49. 10.1038/s41565-018-0246-410.1038/s41565-018-0246-4 ↗
50. 10.1007/s11095-019-2578-710.1007/s11095-019-2578-7 ↗
51. 10.1093/oxfordjournals.jbchem.a00326110.1093/oxfordjournals.jbchem.a003261 ↗
52. 10.1016/j.addr.2016.06.00510.1016/j.addr.2016.06.005 ↗
53. 10.1016/j.ijpharm.2017.07.00110.1016/j.ijpharm.2017.07.001 ↗
54. 10.1016/j.xphs.2016.09.02910.1016/j.xphs.2016.09.029 ↗
55. 10.1016/j.jconrel.2016.06.01610.1016/j.jconrel.2016.06.016 ↗
56. 10.1016/j.addr.2016.07.00710.1016/j.addr.2016.07.007 ↗
57. 10.1016/j.jconrel.2014.10.02610.1016/j.jconrel.2014.10.026 ↗
58. 10.1016/j.actbio.2019.03.01010.1016/j.actbio.2019.03.010 ↗
59. 10.1038/s41598-019-39107-310.1038/s41598-019-39107-3 ↗